"Gliclazide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Descriptor ID |
D005907
|
| MeSH Number(s) |
D02.886.590.795.475 D02.948.828.475
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gliclazide".
Below are MeSH descriptors whose meaning is more specific than "Gliclazide".
This graph shows the total number of publications written about "Gliclazide" by people in this website by year, and whether "Gliclazide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Gliclazide" by people in Profiles.
-
SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochem Biophys Res Commun. 2020 09 10; 530(1):10-14.
-
A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes. J Diabetes Res. 2018; 2018:2791584.
-
Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid? Eur J Dermatol. 2018 Jun 01; 28(3):396-397.
-
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
-
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17. Int J Clin Pract. 2018 Apr; 72(4):e13080.
-
Missed Opportunities for Deprescription: A Teachable Moment. JAMA Intern Med. 2017 07 01; 177(7):1028-1029.
-
Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes. J Assoc Physicians India. 2017 Jun; 65(6):38-41.
-
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Sci China Life Sci. 2017 Mar; 60(3):225-238.
-
Formulation, Characterization and In-vitro Evaluation of Fast Dissolv ing Tablets Containing Gliclazide Hydrotropic Solid Dispersions. Recent Pat Drug Deliv Formul. 2017; 11(2):147-154.